PL2637664T3 - Compositions and methods of treating pulmonary hypertension - Google Patents

Compositions and methods of treating pulmonary hypertension

Info

Publication number: PL2637664T3
Authority: PL; Poland
Prior art keywords: compositions; methods; pulmonary hypertension; treating pulmonary; treating
Prior art date: 2010-10-15

Application number

PL11833507T

Other languages

Polish (pl)

Inventor

Luiz Belardinelli

Hunter Campbell Gillies

Faquan Liang

John Shryock

Suya Yang

Original Assignee

Gilead Sciences, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-15

Filing date

2011-10-14

Publication date

2017-09-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45939010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2637664(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-10-14 Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.

2017-09-29 Publication of PL2637664T3 publication Critical patent/PL2637664T3/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PL11833507T 2010-10-15 2011-10-14 Compositions and methods of treating pulmonary hypertension PL2637664T3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US39352910P	2010-10-15	2010-10-15
US201161490454P	2011-05-26	2011-05-26
US201161497475P	2011-06-15	2011-06-15

Publications (1)

Publication Number	Publication Date
PL2637664T3 true PL2637664T3 (en)	2017-09-29

Family

ID=45939010

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11833507T PL2637664T3 (en)	2010-10-15	2011-10-14	Compositions and methods of treating pulmonary hypertension

Country Status (26)

Country	Link
US (3)	US20120269898A1 (en)
EP (2)	EP3106163A1 (en)
JP (2)	JP5806320B2 (en)
KR (2)	KR20150002876A (en)
CN (1)	CN103458690B (en)
AR (1)	AR083422A1 (en)
AU (2)	AU2011315891B2 (en)
BR (1)	BR112013008983A2 (en)
CA (1)	CA2814518C (en)
CY (1)	CY1119007T1 (en)
DK (1)	DK2637664T3 (en)
EA (2)	EA201691759A1 (en)
ES (1)	ES2627944T3 (en)
HR (1)	HRP20170848T1 (en)
HU (1)	HUE033346T2 (en)
LT (1)	LT2637664T (en)
MX (1)	MX346730B (en)
NZ (2)	NZ610012A (en)
PL (1)	PL2637664T3 (en)
PT (1)	PT2637664T (en)
RS (1)	RS56135B1 (en)
SI (1)	SI2637664T1 (en)
SM (1)	SMT201700297T1 (en)
TW (1)	TWI542580B (en)
WO (1)	WO2012051559A2 (en)
ZA (1)	ZA201302746B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080139593A1 (en)	2006-12-12	2008-06-12	Gerber Michael J	Method for treating a pulmonary hypertension condition
JP5806320B2 (en)	2010-10-15	2015-11-10	ギリアードサイエンシーズ，インコーポレイテッド	Compositions and methods for treating pulmonary hypertension
WO2014003678A1 (en) *	2012-06-28	2014-01-03	Xspray Microparticles Ab	Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2014174529A2 (en) *	2013-04-23	2014-10-30	Hetero Research Foundation	Polymorphs of avanafil
WO2015069839A1 (en) *	2013-11-06	2015-05-14	Gilead Sciences, Inc.	Combination therapy for treating pulmonary hypertension
CN105581990A (en) *	2014-08-27	2016-05-18	人福医药集团股份公司	Ambrisentan tablet and preparation method thereof
AU2016233426B2 (en) *	2015-03-13	2021-08-19	Rita Maria CUNHA DE ALMEIDA	Targeting cGMP-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods
MD3496739T2 (en)	2016-07-15	2021-09-30	Acceleron Pharma Inc	Compositions comprising actriia polypeptides for use in treating pulmonary hypertension
MX389551B (en)	2016-10-27	2025-03-20	Pulmokine Inc	POLYTHERAPY TO TREAT PULMONARY HYPERTENSION.
WO2019010445A1 (en) *	2017-07-07	2019-01-10	The Regents Of The University Of Colorado, A Body Corporate	Compositions and method for treating pulmonary hypertension
CN111683683A (en)	2017-12-26	2020-09-18	Ftf药业私人有限公司	Liquid oral formulations of PDE V inhibitors
CN109406688A (en) *	2018-09-28	2019-03-01	中国食品药品检定研究院	Standard sample for illegal drug in testing product
MX2022006403A (en)	2019-11-29	2022-08-25	Actelion Pharmaceuticals Ltd	Methods of treating pulmonary arterial hypertension.
US11969424B2 (en)	2019-12-16	2024-04-30	Tenax Therapeutics, Inc.	Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)
KR102606504B1 (en) *	2020-04-10	2023-11-29	주식회사 대웅테라퓨틱스	Composition for preventing and treating pulmonary hypertension comprising niclosamide
CN112826944B (en) *	2021-01-29	2023-08-15	台州职业技术学院	Ambrisentan inclusion compound and preparation method thereof
EP4456897A4 (en)	2021-12-31	2025-12-10	Tenax Therapeutics Inc	Oral formulations of levosimendan for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US4326525A (en)	1980-10-14	1982-04-27	Alza Corporation	Osmotic device that improves delivery properties of agent in situ
US5364620A (en)	1983-12-22	1994-11-15	Elan Corporation, Plc	Controlled absorption diltiazem formulation for once daily administration
US4902514A (en)	1988-07-21	1990-02-20	Alza Corporation	Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5250534A (en)	1990-06-20	1993-10-05	Pfizer Inc.	Pyrazolopyrimidinone antianginal agents
DE4313412A1 (en)	1993-04-23	1994-10-27	Basf Ag	3- (Het) aryl-carboxylic acid derivatives, processes and intermediates for their preparation
GB9401090D0 (en)	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
DE19533023B4 (en)	1994-10-14	2007-05-16	Basf Ag	New carboxylic acid derivatives, their preparation and use
PT1049695E (en)	1997-11-12	2002-07-31	Bayer Ag	IMIDAZOTRIAZINONES 2-PHENYL SUBSTITUTED AS PHOSPHODIESTERASE INHIBITORS
US6821975B1 (en)	1999-08-03	2004-11-23	Lilly Icos Llc	Beta-carboline drug products
CA2572179A1 (en)	2004-06-23	2006-01-19	Myogen, Inc.	Enoximone formulations and their use in the treatment of pde-iii mediated diseases
US20060205733A1 (en)	2004-08-26	2006-09-14	Encysive Pharmaceuticals	Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
CN101072564A (en) *	2004-08-26	2007-11-14	恩希赛弗制药公司	Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof
WO2007122466A1 (en)	2006-04-21	2007-11-01	Pfizer Products Inc.	Pyridine[3,4-b]pyrazinones
WO2008073927A1 (en) *	2006-12-12	2008-06-19	Gilead Colorado, Inc.	Ambrisentan combined with a renin inhibitor for hypertensive disorder
US20080139593A1 (en) *	2006-12-12	2008-06-12	Gerber Michael J	Method for treating a pulmonary hypertension condition
CA2695259C (en)	2007-07-31	2016-05-24	Gilead Colorado, Inc.	Metabolites and derivatives of ambrisentan
WO2010062640A1 (en)	2008-10-28	2010-06-03	Gilead Colorado, Inc.	Methods for treating idiopathic pulmonary fibrosis and associated complications
JP5806320B2 (en)	2010-10-15	2015-11-10	ギリアードサイエンシーズ，インコーポレイテッド	Compositions and methods for treating pulmonary hypertension

2011
- 2011-10-14 JP JP2013534043A patent/JP5806320B2/en not_active Expired - Fee Related
- 2011-10-14 AU AU2011315891A patent/AU2011315891B2/en active Active
- 2011-10-14 CN CN201180060879.3A patent/CN103458690B/en not_active Expired - Fee Related
- 2011-10-14 LT LTEP11833507.4T patent/LT2637664T/en unknown
- 2011-10-14 SM SM20170297T patent/SMT201700297T1/en unknown
- 2011-10-14 DK DK11833507.4T patent/DK2637664T3/en active
- 2011-10-14 HR HRP20170848TT patent/HRP20170848T1/en unknown
- 2011-10-14 BR BR112013008983A patent/BR112013008983A2/en not_active IP Right Cessation
- 2011-10-14 SI SI201131190A patent/SI2637664T1/en unknown
- 2011-10-14 RS RS20170640A patent/RS56135B1/en unknown
- 2011-10-14 EA EA201691759A patent/EA201691759A1/en unknown
- 2011-10-14 NZ NZ610012A patent/NZ610012A/en active IP Right Revival
- 2011-10-14 KR KR20147032816A patent/KR20150002876A/en not_active Ceased
- 2011-10-14 KR KR1020137012382A patent/KR20130069855A/en not_active Ceased
- 2011-10-14 PT PT118335074T patent/PT2637664T/en unknown
- 2011-10-14 US US13/274,013 patent/US20120269898A1/en not_active Abandoned
- 2011-10-14 EA EA201390428A patent/EA026074B1/en active IP Right Revival
- 2011-10-14 HU HUE11833507A patent/HUE033346T2/en unknown
- 2011-10-14 PL PL11833507T patent/PL2637664T3/en unknown
- 2011-10-14 CA CA2814518A patent/CA2814518C/en not_active Expired - Fee Related
- 2011-10-14 EP EP16180914.0A patent/EP3106163A1/en not_active Withdrawn
- 2011-10-14 MX MX2013004190A patent/MX346730B/en active IP Right Grant
- 2011-10-14 NZ NZ707213A patent/NZ707213A/en active IP Right Revival
- 2011-10-14 EP EP11833507.4A patent/EP2637664B1/en not_active Revoked
- 2011-10-14 ES ES11833507.4T patent/ES2627944T3/en active Active
- 2011-10-14 TW TW100137481A patent/TWI542580B/en not_active IP Right Cessation
- 2011-10-14 WO PCT/US2011/056404 patent/WO2012051559A2/en not_active Ceased
- 2011-10-17 AR ARP110103833A patent/AR083422A1/en unknown
2013
- 2013-04-17 ZA ZA2013/02746A patent/ZA201302746B/en unknown
- 2013-11-13 US US14/079,548 patent/US9549926B2/en active Active
2015
- 2015-06-10 JP JP2015117196A patent/JP2015178528A/en not_active Withdrawn
2016
- 2016-07-04 AU AU2016204638A patent/AU2016204638B2/en not_active Ceased
- 2016-08-09 US US15/232,570 patent/US20160346280A1/en not_active Abandoned
2017
- 2017-06-22 CY CY20171100660T patent/CY1119007T1/en unknown

Also Published As

Publication number	Publication date
CA2814518C (en)	2016-09-20
BR112013008983A2 (en)	2016-07-05
HRP20170848T1 (en)	2017-08-25
EP2637664B1 (en)	2017-03-29
JP2014506870A (en)	2014-03-20
HUE033346T2 (en)	2017-11-28
NZ610012A (en)	2015-05-29
AU2011315891A1 (en)	2013-05-23
RS56135B1 (en)	2017-10-31
EP2637664A4 (en)	2014-09-10
EP3106163A1 (en)	2016-12-21
US9549926B2 (en)	2017-01-24
EA201390428A1 (en)	2014-02-28
SI2637664T1 (en)	2017-07-31
AR083422A1 (en)	2013-02-21
AU2016204638B2 (en)	2018-06-07
US20120269898A1 (en)	2012-10-25
JP5806320B2 (en)	2015-11-10
EA201691759A1 (en)	2017-05-31
CY1119007T1 (en)	2018-01-10
AU2011315891B2 (en)	2015-08-13
US20140275098A1 (en)	2014-09-18
JP2015178528A (en)	2015-10-08
TWI542580B (en)	2016-07-21
CN103458690A (en)	2013-12-18
CA2814518A1 (en)	2012-04-19
LT2637664T (en)	2017-11-10
MX346730B (en)	2017-03-30
WO2012051559A2 (en)	2012-04-19
KR20130069855A (en)	2013-06-26
DK2637664T3 (en)	2017-06-19
WO2012051559A3 (en)	2013-10-17
EA026074B1 (en)	2017-02-28
US20160346280A1 (en)	2016-12-01
PT2637664T (en)	2017-06-22
EP2637664A2 (en)	2013-09-18
NZ707213A (en)	2016-12-23
ZA201302746B (en)	2014-06-25
ES2627944T3 (en)	2017-08-01
TW201219372A (en)	2012-05-16
CN103458690B (en)	2016-03-16
MX2013004190A (en)	2013-07-29
KR20150002876A (en)	2015-01-07
AU2016204638A1 (en)	2016-08-04
SMT201700297T1 (en)	2017-07-18

Publication	Publication Date	Title
ZA201302746B (en)	2014-06-25	Compositions and methods of treating pulmonary hypertension
IL250824B (en)	2019-03-31	Certain amino-pyridazines, compositions thereof, and methods of their use
EP2603202A4 (en)	2016-06-01	Compositions and methods for treatment of taupathy
EP2534205A4 (en)	2014-11-05	Rheology modifier compositions and methods of use
EP2603199A4 (en)	2014-01-01	Compositions and methods for treating cardiovascular disease
IL232977B (en)	2019-01-31	Intranasal dexmedetomidine compositions and methods of use thereof
EP2675471A4 (en)	2015-01-28	Hsa-related compositions and methods of use
IL222291A0 (en)	2012-12-31	Compositions and methods of synthesis of pyridinoylpiperidine
EP2655334A4 (en)	2014-12-31	Compositions and methods useful for treating diseases
EP2633046A4 (en)	2015-05-06	Compositions and methods for inhibition of pcsk9 genes
EP2593571A4 (en)	2015-09-30	Sweetener compositions and methods of making same
EP2771030A4 (en)	2015-07-22	Compositions and methods for treatment of proteinopathies
SG10201500165RA (en)	2015-03-30	Abradable composition and method of manufacture
EP2576579A4 (en)	2014-08-13	Compositions and methods directed to treating liver fibrosis
IL225488A0 (en)	2013-06-27	Compositions and methods for treatment of hematological malignancies
EP2622029A4 (en)	2014-06-04	Deinking compositions and methods of use
IL225389A0 (en)	2013-06-27	Antibody compositions and methods of use
IL220715A0 (en)	2012-08-30	Nutritive compositions and methods of using same
EP2590674A4 (en)	2014-09-10	Compositions and methods for treating influenza
IL227924A0 (en)	2013-09-30	Compositions and methods of use for determination of he4a
WO2011137427A9 (en)	2012-04-12	Compositions and methods for treating pulmonary conditions
IL253853A0 (en)	2017-09-28	Methods and compositions for treating or preventing symptoms of hormonal variations
EP2566485A4 (en)	2014-03-12	Immunostimulatory compositions and methods of use thereof
GB201018650D0 (en)	2010-12-22	Methods and compositions
EP2672968A4 (en)	2016-07-13	Econazole composition and methods of treatment therewith